

GENOME THERAPEUTICS CORP  
Form 8-K  
October 16, 2001

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT  
Pursuant to  
Section 13 or 15(d) of  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 15, 2001

-----  
GENOME THERAPEUTICS CORP.  
(Exact name of registrant as specified in its charter)

MASSACHUSETTS	0-10824	04-2297484
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

100 BEAVER STREET  
WALTHAM, MASSACHUSETTS 02453  
(Address, of principal executive offices, including zip code)

(781) 398-2300  
(Registrant's Telephone number including area code)

-----  
PAGE 1 OF 4 PAGES.

Item 5. OTHER EVENTS

On October 15, 2001, Genome Therapeutics Corp. issued a press release announcing that researchers from Genome Therapeutics and Creighton University have identified a novel gene responsible for high bone density. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Stephen Cohen

-----  
Name: Stephen Cohen  
Title: Chief Financial Officer

Date: October 16, 2001

EXHIBIT INDEX

99.1 Press Release dated October 15, 2001